

眼科学

論文

A 欧文

A-a

1. Kawashima Y, Hata M, Miyake M, Kusaka M, Oishi A, Ooto S, Tamura H, Miyata M, Uji A, Ueda-Arakawa N, Takahashi A, Tsujikawa A: MACULAR CHORIORETINAL ATROPHY AND VISUAL OUTCOMES IN RANIBIZUMAB- OR AFLIBERCEPT-TREATED MYOPIC CHOROIDAL NEOVASCULARIZATION. *Retina* 44(1): 127-135, 2024. doi: 10.1097/IAE.0000000000003930. *
2. Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vittori R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S: PHOTON Investigators: Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. *Lancet* 403(10432): 1153-1163, 2024. doi: 10.1016/S0140-6736(23)02577-1. *
3. Muramatsu A, Nakamura S, Hirayama T, Nagasawa H, Ohira A, Kitaoka T, Hara H, Shimazawa M: Both hemoglobin and hemin cause damage to retinal pigment epithelium through the iron ion accumulation. *J Pharmacol Sci* 155(2): 44-51, 2024. doi: 10.1016/j.jphs.2024.04.001. *
4. Otsuka Y, Imamura K, Oishi A, Asakawa K, Kondo T, Nakai R, Suga M, Inoue I, Sagara Y, Tsukita K, Teranaka K, Nishimura Y, Watanabe A, Umeyama K, Okushima N, Mitani K, Nagashima H, Kawakami K, Muguruma K, Tsujikawa A, Inoue H: Phototoxicity avoidance is a potential therapeutic approach for retinal dystrophy caused by EYS dysfunction. *JCI Insight* 9(8): e174179, 2024. doi: 10.1172/jci.insight.174179. *
5. Machida A, Oishi A, Ikeda J, Kurihara J, Yoneda A, Tsuiki E, Hirata Y, Murakami R, Kitaoka T: Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. *Life (Basel)* 14(4): 476, 2024. doi: 10.3390/life14040476. *
6. Fujinami K, Nishiguchi KM, Oishi A, Akiyama M, Ikeda Y; Research Group on Rare, Intractable Diseases (Ministry of Health, Labour, Welfare of Japan): Specification of variant interpretation guidelines for inherited retinal dystrophy in Japan. *Jpn J Ophthalmol* 68(4): 389-399, 2024. doi: 10.1007/s10384-024-01063-5. *
7. Ikeda HO, Hasegawa T, Abe H, Amino Y, Nakagawa T, Tada H, Miyata M, Oishi A, Morita S, Tsujikawa A: Efficacy and Safety of Branched Chain Amino Acids on Retinitis Pigmentosa: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Transl Vis Sci Technol* 13(8): 29, 2024. doi: 10.1167/tvst.13.8.29. *
8. Saito J, Machida A, Inoue D, Shimizu MS, Matsui K, Harada K, Kusano M, Mohamed YH, Uematsu M: A Case of Parinaud Oculoglandular Syndrome in Which Bartonella DNA Was Detected in the Cornea and Conjunctiva by Polymerase Chain Reaction. *Medicina* 60(9): 1425, 2024. doi: 10.3390/medicina60091425.
9. Mohamed YH, Uematsu M, Kusano M, Inoue D, Tang D, Suzuki K, Kitaoka T: A Novel Technique for Corneal Transepithelial Electrical Resistance Measurement in Mice. *Life (Basel)* 14(8): 1046, 2024. doi: 10.3390/life14081046. ★
10. Mohamed YH, Uematsu M, Kusano M, Kitaoka T, Nishida T: Is it really descemetocoele? Morphology of extremely thin membrane that remained after severe corneal melting: a case report. *Med Mol Morphol* 58(1): 69-74, 2024. doi: 10.1007/s00795-024-00405-z. *
11. Mohamed MT, Inoue D, Yoshimura S, Uematsu M, Mohamed YH, Kusano M, Tang D, Oishi A, Kitaoka T, Takeo G, Ohira A: Neuronal Intranuclear Inclusion Disease with a Corneal Disorder: A Case Report. *Medicina (Kaunas)* 60(11): 1730, 2024. doi: 10.3390/medicina60111730.
12. Akiyama F, Matsumoto K, Yamashita K, Oishi A, Kitaoka T, Ueda HR: A multiwell plate approach to increase the sample throughput during tissue clearing. *Nat Protoc* 20(4): 967-988, 2024. doi: 10.1038/s41596-024-01080-1. *
13. Harada S, Mohamed YH, Kusano M, Inoue D, Uematsu M: Bilateral Fuchs' Superficial Marginal Keratitis Diagnosis and Treatment. *Life* 14(12): 1644, 2024. doi: 10.3390/life14121644. *
14. Ashizuka T, Uematsu M, Mohamed MT, Kusano M, Mohamed YH, Inoue D, Kitaoka T: A case of corneal opacity caused by atovaquone administration. *Am J Ophthalmol Case Rep* 12(37): 102235, 2024. doi: 10.1016/j.ajoc.2024.102235. eCollection 2025 Mar.

A-e-1

1. Oishi A, Machida A, Tsuiki E, Miyagi S, Hirata Y, Murakami R, Oka A, Yoneda A, Kurihara J: one+ treat and extend regimen using faricimab in patients with neovascular age-related macular degeneration. *Invest. Ophthalmol. Vis. Sci* 65(7): 4385, 2024.
2. Uematsu M, Kosai K, Kusano M, Sasaki D, Inoue D, Mohamed YH, Tang D, Mohamed MT, Yanagihara K: 16S rRNA metagenomic analysis of bacterial flora in patients with chronic dacryocystitis. *Invest. Ophthalmol. Vis. Sci* 65(7): 6533, 2024.
3. Miyagi S, Tsuiki E, Oishi A: Elliptic Fourier analysis in the retinal contour of epiretinal membrane. *Invest. Ophthalmol. Vis. Sci* 65(7): 4832, 2024.
4. Oka A, Murakami R, Machida A, Miyagi S, Tsuiki E, Kurihara J, Oishi A: Subretinal fibrosis and after anti-VEGF therapy for macular neovascularization associated with drusen and/or pachychoroid phenotype. *Invest. Ophthalmol. Vis. Sci* 65(7): 240, 2024.

5. Mohamed YH, Uematsu M, Kusano M, Inoue D, Tang D, Kitaoka T: BAC-induced Changes in Mouse Corneal Transepithelial Electrical Resistance. Invest. Ophthalmol. Vis. Sci 65(7): 1995, 2024.

B 邦文

B-a

1. 平山勝大, 岸川泰宏, 大石明生: 多汗症治療薬グリコピロニウムトシル酸塩水和物使用に関連した片眼性瞳孔散大の1例. 眼科 66(6): 593-598, 2024.
2. 磯本翔吾, 宮城清弦, 河野良太, 原田史織, 北岡 隆: ステロイドパルス施行後に眼窩内腫瘍と細菌性眼内炎が明らかになった1例. 臨床眼科 78(10): 1241-1245, 2024.

B-b

1. 上松聖典: III 治療 8. 羊膜移植. 新篇 眼科プラクティス 15: 256-261, 2024.
2. 原田康平: 6) Ocular surface squamous neoplasia. 新篇 眼科プラクティス 15: 131-134, 2024.
3. 北岡 隆: 眼内異物除去術に必要な手術解剖. 眼科医のための手術解剖: 141-144, 2024.
4. 大石明生: VIII. 網膜 Dry AMD. 臨床眼科増刊号 78(11): 246-249, 2024.
5. 大石明生: 5 異常所見の見方④網膜剥離. 京都大学版 基礎からのOCT・OCTA入門: 47-49, 2024.
6. 上松聖典: 3 再発翼状片手術. 眼科レジデントのためのベーシック手術 第2版: 135-142, 2024.

論文研究業績集計表

論文数一覧

	A-a	A-b	A-c	A-d	A-e	合計	SCI	B-a	B-b	B-c	B-d	B-e	合計	総計
2024	14	0	0	0	5	19	11	2	6	0	0	0	8	27

学会発表数一覧

	A-a	A-b シンポジウム	A-b 学会	合計	B-a	B-b シンポジウム	B-b 学会	合計	総計
2024	0	0	5	5	0	1	17	18	23

論文総数に係る教員生産係数一覧

	欧文論文総数 論文総数	教員生産係数 (欧文論文)	SCI 掲載論文数 欧文論文総数	教員生産係数 (SCI 掲載論文)
2024	0.704	1.583	0.579	0.917